News headlines about Endologix (NASDAQ:ELGX) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a news impact score of 0.18 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 46.8587928489129 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Endologix Reports Positive One-Year Results From the Ovation LUCY Study (dicardiology.com)
- Endologix, Inc. to Announce Second Quarter 2018 Financial Results on August 9, 2018 (finance.yahoo.com)
- Stock Under Active Eyes: Endologix, Inc. (ELGX) (bitcoinpriceupdate.review)
- Endologix, Inc. (ELGX) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Endologix Inc. to Post FY2016 Revenue of ($0.71) Per Share, Leerink Swann Forecasts (ELGX) (bharatapress.com)
NASDAQ:ELGX traded down $0.09 on Tuesday, hitting $5.42. 4,339 shares of the stock were exchanged, compared to its average volume of 483,122. The firm has a market capitalization of $462.06 million, a PE ratio of -11.31 and a beta of 0.44. The company has a debt-to-equity ratio of 3.58, a current ratio of 2.13 and a quick ratio of 1.37. Endologix has a fifty-two week low of $3.75 and a fifty-two week high of $6.72.
ELGX has been the subject of several analyst reports. BidaskClub upgraded Endologix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 24th. ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a research note on Thursday, May 17th. Zacks Investment Research upgraded Endologix from a “sell” rating to a “hold” rating in a research note on Monday, May 7th. Stifel Nicolaus upped their target price on Endologix from $4.50 to $5.00 and gave the company a “hold” rating in a research note on Monday, May 21st. Finally, Oppenheimer set a $5.00 target price on Endologix and gave the company a “hold” rating in a research note on Thursday, May 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $4.95.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: Understanding Analyst Recommendations
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.